Lumen Bioscience and Novo Nordisk Enter into Research Collaboration to Explore Novel Strategies to Deliver Oral Biologics for Cardiometabolic Disease

by admin | Jun 16, 2021 | Press Release

Seattle, WA, June 16, 2021 – Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, announced today it has entered into a research collaboration with Novo Nordisk to evaluate the use of Lumen’s unique drug...

Lumen and Novo Nordisk link up on oral biologics for cardiometabolic disease

by admin | Jun 16, 2021 | Press Release

Novo Nordisk Partners With Seattle Biopharm to Research, Develop Obesity Therapies

by admin | Jun 16, 2021 | Press Release

Lumen Bioscience Announces Appointment of Marcos Milla, Ph.D. to Board of Directors & Expansion of Leadership Team

by admin | Apr 21, 2021 | Press Release

Seattle, WA, April 22, 2020 – Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the appointment of Marcos Milla, Ph.D., to the company’s board of directors and the expansion of its...

Developing a biologic to prevent gastrointestinal diseases

by admin | Mar 30, 2021 | Press Release